Vitrectomy combined with intravitreal triamcinolone acetonide injection for diabetic macular edema
Not Applicable
- Conditions
- Diabetic macular edema
- Registration Number
- JPRN-UMIN000017250
- Lead Sponsor
- Tohoku University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
History of previous vitrectomy. Previous history of treatment with agents including triamcninolone acetonide, anti-VEGF therapy, immunosuppressant drugs and artificial dialysis within 24 weeks. Modification of insulin treatments within 12 weeks. Previous history of laser treatments or intraocular surgery within 12 weeks. Previous history of systemic drugs such as steroid, carbonate dehydratase inhibitor and warfarin within 4 weeks.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Central retinal thickness
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the anti-inflammatory effects of triamcinolone acetonide in diabetic macular edema treatment?
How does vitrectomy combined with IVTA compare to anti-VEGF therapy in managing persistent DME?
Are there specific biomarkers that predict response to intravitreal corticosteroid treatment in DME patients?
What are the long-term adverse event profiles of intravitreal triamcinolone acetonide in diabetic retinopathy?
What combination therapies are being explored alongside corticosteroids for diabetic macular edema?